Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. - Wikidata - awgldk - TriplyDB

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

http://www.wikidata.org/entity/Q37700097

about

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma.Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers

P2860

Q33890558-4A4FA53B-53C9-498E-8967-BC15CB4AA402 Q45824718-CCB86B14-9C6B-4C35-AF17-83411F6F662C Q52590673-FABD3BAE-EC41-45D0-962A-D1BD312D7619 Q55459882-50255AAC-71AA-4AA1-A6B6-5F18E3B95452 Q58698940-0A2EF627-1FCE-4EFB-8B8E-D3048A44F16E

P2860

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

http://www.wikidata.org/entity/Q37700097

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@en

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@nl

type

label

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@en

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@nl

prefLabel

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@en

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@nl

P1433

Q37700097-2369AA15-6097-43D7-A096-53223F432B46

P1476

Q37700097-07881293-2294-45EB-B661-38528DF710B4

P2093

Q37700097-07888CAA-467D-4E97-A866-47AC24C69FA1

Q37700097-0F7127EC-A33C-4800-8FB2-C13302CE4727

Q37700097-2B2287CD-5F5E-4459-A094-17FE449E0736

Q37700097-2D81E210-279B-4DFA-B45D-A01E1034A684

Q37700097-508EE318-41B7-4730-A637-9C8872E62ED6

Q37700097-6FE2FD1B-E312-4B9C-BC55-B1032B6C4845

Q37700097-94DA478C-CC15-47ED-B8EC-C128271A0920

Q37700097-99C5D933-0A80-464E-B94D-05BE86F53B02

Q37700097-9E97F7AD-240F-4541-836D-DCECF3E164A6

Q37700097-B3948EF5-88BC-4C8A-B4C3-427A0F5F89FD

P2860

Q37700097-01BBAA62-FE2E-4F95-81BB-5C492D8FC002

Q37700097-04DBD8F8-5C00-42AB-8F7F-250EE888CE64

Q37700097-170E63B3-EDEA-4293-BA0E-A8B3065D7999

Q37700097-1D2D27BA-BABB-43B1-825D-27601A887EEC

Q37700097-1E99F248-1487-44F7-B7D0-68B50F39DBA1

Q37700097-216EE8CD-1764-4BD6-9717-319469B039C4

Q37700097-293A4D19-8FA7-4AC1-B54F-E209BB6F5ACA

Q37700097-2C3E7153-8384-4320-A607-09D626760C04

Q37700097-2EBA2F6D-CD0B-4576-A8CA-1C9FB11C592D

Q37700097-2FBBCC12-5D67-4388-8F86-1DD947A5F2DA

P304

Q37700097-F5CF6EE1-D9F9-4AC0-BEB4-0C42AD5A2B21

P31

Q37700097-2A637BBE-C291-4F89-BF52-82394E4A797A

P356

Q37700097-AD4FFD1D-FE19-4A06-B01D-6E6DA1E43FAE

P478

Q37700097-3CD7E4AA-0863-4647-9FCB-A8F5934031CE

P50

Q37700097-31420417-83A9-4132-A5A7-134618B8536A

Q37700097-F7AE3AE4-717F-428C-B43F-AA3038ED5054

P577

Q37700097-9958A7EA-C18A-4D8C-9F69-DAB3B482B113

P698

Q37700097-258AA2B0-1905-4FAE-8D7D-E4A3F1A3CFC7

P921

Q37700097-8784B206-820B-4BD3-8599-DE1F55DDDF59

Q37700097-C824CBBF-42BB-42CE-A71F-227EC4A0857F

P932

Q37700097-A5E1B91E-6A06-4349-9A10-15B2C9C4532C

P356

P1433

Disease Markers

P1476

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.

@en

P2093

Guoqing Ru

http://www.w3.org/2001/XMLSchema#string

Junqiang Chen

http://www.w3.org/2001/XMLSchema#string

Lijin Zhu

http://www.w3.org/2001/XMLSchema#string

Min Yu

http://www.w3.org/2001/XMLSchema#string

Riping Chen

http://www.w3.org/2001/XMLSchema#string

Tao Li

http://www.w3.org/2001/XMLSchema#string

Wanyuan Chen

http://www.w3.org/2001/XMLSchema#string

Xianglei He

http://www.w3.org/2001/XMLSchema#string

Xianhong Yin

http://www.w3.org/2001/XMLSchema#string

Xing Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1

HMGB1 and RAGE in inflammation and cancer

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma

A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

High-mobility group box 1 and cancer.

Expression and effects of high-mobility group box 1 in cervical cancer.

Epidemiology of occupational asbestos-related diseases in China.

Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.

P304

5756102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/5756102

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28348451

http://www.w3.org/2001/XMLSchema#string

P921

P932

5350493

http://www.w3.org/2001/XMLSchema#string